![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2008, American Society for Microbiology Disruption of the Fbxw8 Gene Results in Pre- and Postnatal Growth Retardation in Mice † Department of Medical Oncology, Dana-Farber Cancer Institute,1 Department of Medicine, Brigham and Women's Hospital,2 Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts3 *Corresponding author. Mailing address: Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115. Phone: (617) 632-3825. Fax: (617) 582-8601. E-mail: james_decaprio/at/dfci.harvard.edu Received September 8, 2007; Revised October 22, 2007; Accepted October 30, 2007. This article has been cited by other articles in PMC.Abstract CUL7 binds to SKP1, RBX1, and FBXW8 to form a cullin-RING ligase, or an SKP1-cullin-F box protein complex. The targeted disruption of the Cul7 gene in mice results in significant reduction in embryo size and neonatal lethality. In humans, CUL7 was found to be mutated in the 3-M dwarfism syndrome characterized by severe pre- and postnatal growth retardation, indicating that CUL7 is closely associated with human and mouse growth. We generated mice lacking Fbxw8 by gene trapping. Similar to Cul7−/− animals, Fbxw8−/− embryos and placentas were smaller than wild-type and heterozygous littermates and placentas. Approximately 30% of the expected number of Fbxw8−/− mice survived birth, but these mice remained smaller than their wild-type and heterozygous littermates throughout postnatal development. FBXW8 expression was detected in most organs of wild-type mice examined, and the organs in Fbxw8−/− mice were smaller than those in wild-type mice. Fbxw8 expression levels were highest in skeletal muscle, cartilage, and lung tissue. Expression profiling revealed elevated levels of insulin-like growth factor binding protein 1 (IGFBP1) transcripts in Fbxw8−/− embryos. Furthermore, we observed increased levels of IGFBP2 in Cul7−/− as well as Fbxw8−/− fibroblasts. These results demonstrate that the FBXW8-CUL7 complex plays a significant role in growth control. The ubiquitin-proteasome pathway of protein degradation plays an important role in many biological processes, including cell cycle progression, transcription, and signal transduction. A cascade of three enzymes is involved in the ubiquitin transfer process: the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme, and the E3 ubiquitin ligase (10). The E3 ubiquitin ligase determines substrate specificity, with subsequent ubiquitination regulated by the E3 activity or the E3-substrate interaction (8). The E3 SKP1-cullin-F box protein (SCF) complex is a well-characterized cullin-RING ligase (CRL) in which CUL1 serves as a scaffold that binds to RBX1, which in turn recruits E2, SKP1, and the F box-containing protein that defines the substrate specificity (13). Sixty-eight human and 74 mouse genes encoding F box-containing proteins have been identified (14). CUL7 was isolated as a simian virus 40 large T antigen-associated protein and is a member of the CRL family that forms a complex with RBX1, SKP1, and the F box protein FBXW8 (previously referred to as Fbx29 and Fbw6) (1, 2, 9, 15). FBXW8 contains an N-terminal F box motif required for SKP1 binding and a C-terminal WD40 repeat that, by analogy to other FBXW proteins, is predicted to mediate interactions with substrate proteins. CUL7 has not been reported to interact with any other F box protein besides FBXW8, unlike CUL1, which interacts with many F box proteins, including β-transducin repeat-containing protein, FBXW7, and SKP2 (22). CUL7 has also been shown to bind to PARC and GLMN (also known as glomulin and FAP68), although the significance of these interactions is less well understood (2, 25, 26). Although the substrates of the CUL7-FBXW8 complex are not known, the Cul7 knockout revealed a significant role in growth and development (2). The targeted disruption of the Cul7 gene in mice resulted in abnormalities in placental development, embryonic growth retardation, and neonatal lethality due to respiratory failure (2). In addition, Cul7−/− mouse embryonic fibroblasts (MEFs) demonstrated a severe proliferation defect compared to MEFs from wild-type or Cul7+/− littermates. Recently, the human CUL7 gene was found to be mutated in individuals with 3-M syndrome, or gloomy-face dwarfism syndrome, characterized by severe pre- and postnatal growth retardation (12, 18). These results indicate an important role for CUL7 in the growth of mice and humans. Given the effects of Cul7 mutation on growth, we asked if the disruption of the Fbxw8 gene, encoding the CUL7-associated F box protein, results in a phenotype similar to that of the Cul7 knockout. Fbxw8 null embryos showed severe intrauterine growth retardation, and the majority of the Fbxw8−/− mice died neonatally due to respiratory failure. Some Fbxw8−/− mice survived birth but remained runted during postnatal development compared to their wild-type and heterozygote littermates. We also observed that the expression of CUL7 was dependent on FBXW8 in a wide variety of tissues. In addition, gene expression profiling revealed the up-regulation of insulin-like growth factor binding protein 1 (IGFBP1) transcripts in Fbxw8−/− embryos. In addition, IGFBP2 expression was increased in both Cul7−/− and Fbxw8−/− MEFs. These results indicate that the CUL7-FBXW8 SCF complex regulates pre- and postnatal growth and development. MATERIALS AND METHODS Generation of Fbxw8 gene trap mice. Male chimeric mice generated from the embryonic stem (ES) cell line RRT057 were obtained from BayGenomics (http://www.genetrap.org) (27). The ES cell line RRT057 was generated by using a gene trap protocol with the trapping construct pGTOLxf, containing a splice-acceptor sequence subcloned toward the 5′ end from the β-geo reporter cassette encoding the β-galactosidase (β-Gal)-neomycin resistance fusion protein. The founder chimera was mated with C57BL/6 females. Mice were genotyped by PCR using primers that identified the β-geo insertion and the wild-type Fbxw8 genomic sequence. Primer sequences for Fbxw8 genotyping will be provided upon request. Cell culture. MEFs were established from embryos isolated at embryonic day 14.5 (E14.5) and cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. For growth curves, 105 cells were plated in duplicate into 60-mm dishes and cells were counted twice at 24-h intervals by using a hemocytometer. Serial passage growth over a 3-day interval (expressed as the ratio of the number of cells on day 3 [N3] to the number of cells on day 0 [N0], or the N3/N0 ratio) was determined according to the 3T3 protocol (30). Human lymphoblastoid B-cell lines derived from a 3-M syndrome patient (FY0211) and the patient's parents (FY0212 and FY0213) were obtained from the European Collection of Cell Cultures. Histological analysis. Embryos and placentas from timed matings of Fbxw8+/− mice were fixed in Bouin's fixative (Sigma) and embedded in paraffin. For β-Gal staining, frozen sections of embryos and placentas were prepared and stained according to the protocols of the β-Gal stain manufacturer (Chemicon). Western blotting and immunoprecipitation. MEFs were lysed in NET-N buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) containing protease inhibitor cocktail set I (Calbiochem), and lysates were subjected to immunoblot analysis. For immunoprecipitation, cell lysates were incubated with the corresponding antibody and protein A-Sepharose beads (Amersham) for 3 h and then washed vigorously three times with the lysis buffer before boiling in sodium dodecyl sulfate (SDS) sample buffer. For the determination of tyrosine phosphorylation, MEFs were serum starved for 14 h and treated with a 30-ng/ml concentration of recombinant mouse insulin-like growth factor 1 (IGF1; R&D Systems) for 15 min and then lysed in buffer containing 50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 10 mM NaF, and 5 mM Na3VO4. The rabbit anti-FBXW8 and anti-CUL7 antibodies were generated by Bethyl Laboratories (Montgomery, TX). Additional antibodies used were vinculin (hVIN1; Sigma), SKP1 (Neomarkers), IGFBP2 (R&D Systems), IGF1 receptor (IGF1R [C-20; Santa Cruz]), and phosphotyrosine (PY99; Santa Cruz). siRNA transfection. Short interfering RNA (siRNA) oligonucleotides were obtained from Dharmacon. Sequences of CUL7, FBXW8, and luciferase gene siRNA oligonucleotides were as follows: CUL7 A, AAU CAA CUG CCA UGU CUA CAA; CUL7 B, AAG AUA CUC CAA CUU CUA CAA; FBXW8 N1, AAG AUG UGC ACA GGU GAG CAA; FBXW8 N2, AAG ACG UGG AAG GUG AUU GCA; and luciferase gene siRNA, AAC UUA CGC UGA GUA CUU CGA. Cells in a 6-well plate were transfected with 10 μl of 20 μM oligonucleotides by using Oligofectamine (Invitrogen). Cells were harvested 72 h after transfection and used for immunoblotting. Quantitative PCR. Total RNA was extracted using an RNeasy mini kit (QIAGEN). Three micrograms of RNA was reverse transcribed using the SuperScript III first-strand synthesis system (Invitrogen). Specific cDNA was quantified by using TaqMan gene expression assays, specific primers, probes for mouse Cul7 and Fbxw8 and the mouse β-actin gene, and the real-time PCR 7500 system (Applied Biosystems). Analysis of secreted proteins. Early-passage MEFs were incubated in 100-mm dishes in Opti-MEM (Invitrogen) for 24 h, and supernatants were harvested for trichloroacetic acid precipitation according to the procedure reported recently (19). The precipitate from trichloroacetic acid was subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and stained with Coomassie blue. The band reproducibly differing in abundance was excised and identified using mass spectrometry. Transcriptome profiling and Affymetrix data analysis. RNAs were extracted from E18.5 whole embryos by using TRIzol (Invitrogen), subjected to homogenization followed by RNA cleanup with a QIAGEN system, labeled, and hybridized to an Affymetrix GeneChip Mouse Genome 430 2.0 array. Expression data were processed using the R-Bioconductor package Affy (www.bioconductor.org). The preferred analysis methods (5) were used to generate expression values for each probe set. The details of the analysis will be provided upon request. RESULTS Generation of Fbxw8−/− mice. Mice were generated from ES cells (RRT057) containing an insertion mutation, or gene trap, in the third intron of the Fbxw8 gene. The gene trap vector generates a spliced fusion transcript comprising Fbxw8 and the β-geo cassette encoding β-Gal and neomycin resistance. We determined that the trapping construct was inserted 2.6 kb from the 3′ end of exon 3 of Fbxw8 in the RRT057 cells by sequencing of genomic DNA (Fig. (Fig.1A).1A
To determine if the gene trap reduced FBXW8 protein expression, lysates prepared from MEFs were Western blotted with an antibody against FBXW8. As shown in Fig. Fig.1E,1E Growth retardation of Fbxw8−/− mice. Similar to Cul7+/− mice, heterozygous Fbxw8+/− mice were fertile and indistinguishable in appearance and behavior from their wild-type littermates. An analysis of embryos derived from heterozygote intercrosses revealed that the percentage of Fbxw8−/− mice varied between 22 and 24% at E12.5 to E18.5, indicating that Fbxw8−/− mice were viable until late in gestation, although some fetal loss cannot be excluded since the numbers of Fbxw8−/− as well as Fbxw8+/− embryos were smaller than expected relative to the number of Fbxw8+/+ embryos. Relative to heterozygote littermates, Fbxw8−/− embryos were reduced in size (to 83% of littermate size) at E12.5 and became progressively smaller (to 67% of littermate size) by E18.5 but were otherwise normal in appearance. At each gestational stage, Fbxw8−/− placentas were also significantly reduced in size. The weight of Fbxw8−/− placentas was 60 to 67% that of wild-type placentas, whereas the weights of heterozygous and wild-type placentas were similar to each other (Fig. (Fig.2A2A
All E18.5 embryos recovered from the uteri of Fbxw8+/− intercross mice were alive, as indicated by spontaneous movement and beating hearts. However, all Fbxw8−/− E18.5 embryos (n = 15) were unable to initiate or sustain strong and regular breathing and quickly turned cyanotic. In contrast, nearly all Fbxw8+/+ and Fbxw8+/− E18.5 embryos began spontaneous breathing. A histological examination of lungs obtained from E18.5 embryos revealed reduced alveolar space in Fbxw8−/− lungs (Fig. (Fig.3B)3B
We closely examined all surviving mice from several litters over a number of months. As shown in Fig. Fig.2B,2B Several pairs of Fbxw8−/− and Fbxw8+/+ mice were sacrificed at 3 months of age. FBXW8 protein expression was readily detected in most organs, except for the brains, of wild-type but not Fbxw8−/− mice (Fig. (Fig.2C).2C FBXW8 expression in embryos and placentas. The gene trap vector enabled the determination of the tissue-specific expression pattern of Fbxw8, since the β-geo fusion protein derived from the insertion was under the control of the endogenous Fbxw8 promoter. We assayed for β-Gal expression in histologic sections of Fbxw8−/− embryos and placentas. In E18.5 embryos, β-Gal was highly expressed in skeletal muscle, with intense staining observed in the diaphragms, intercostals, and abdominal walls (Fig. (Fig.3C).3C When Fbxw8−/− mutant placentas were examined, intense β-Gal staining was detected in the labyrinthine layer (Fig. (Fig.3H).3H FBXW8 protein expression and CUL7 protein expression are mutually dependent. We have previously detected the specific interaction of CUL7 with FBXW8 by using epitope tag constructs and have reported that the expression of FBXW8 protein was reduced in Cul7−/− cells compared to that in wild-type MEFs (2, 9). To determine if the endogenous CUL7, FBXW8, and SKP1 proteins interact, immunoprecipitations from MEFs as well as cells from human cell lines were performed with monospecific antibodies against CUL7 and FBXW8 and immunoprecipitates were analyzed by Western blotting. Immunoprecipitation analysis of CUL7 and FBXW8 in mouse and human cells revealed the coprecipitation of these proteins as well as SKP1 (Fig. (Fig.4A4A
We have reported that in Cul7−/− MEFs, FBXW8 protein expression was reduced due to a significantly shorter half-life than that in wild-type MEFs (2). To determine if CUL7 expression was affected by the disruption of the Fbxw8 gene, lysates were prepared from wild-type and Fbxw8 null MEFs, as well as from whole E18.5 embryos and placentas. As shown in Fig. Fig.4B,4B To determine if CUL7 and FBXW8 expression levels were mutually dependent in human cells, we transfected HeLa cells with siRNA against CUL7 or FBXW8. Using two different siRNAs specific for each gene, we observed decreased expression of FBXW8 when CUL7 levels were reduced and reduced levels of CUL7 when FBXW8 was knocked down relative to levels in mock- or control-transfected siRNA-treated cells (Fig. (Fig.4D4D Individuals with 3-M syndrome were previously reported to have mutations in both alleles of CUL7 (12). We determined that the FY211 lymphoblastoid B-cell line derived from an individual with 3-M syndrome contains the mutation 263delT, causing a valine-to-alanine substitution followed by a short nonsense sequence (V88A plus 25 residues) resulting in a truncated protein (see Fig. S1 in the supplemental material). We examined the cell line from the 3-M syndrome patient as well as the heterozygote lines from the patient's parents for CUL7 and FBXW8 protein expression. Full-length CUL7 protein was not detected in lysates prepared from the 3-M cells but could readily be detected in the parental cells (Fig. (Fig.4E).4E Increased IGFBP1 expression in Fbxw8−/− embryos. To explore the phenotype of Fbxw8−/− embryos, transcriptome profiling of E18.5 Fbxw8−/− and Fbxw8+/− whole embryos was carried out. We selected Fbxw8+/− embryos as controls since they also contained the β-geo integrated gene trap that might affect the expression of some genes. Five Fbxw8−/− and five Fbxw8+/− embryos were profiled from an initial batch of three each and a second batch of two each to increase detection power. Though both batches had a large number of genes differentially expressed, when all 10 expression profiles were analyzed together, only Fbxw8, the trapped gene, showed significant differential expression. When results from the two batches of Fbxw8−/− and Fbxw8+/− embryos were compared, only nine genes consistently showed differential expression in the same direction, with a q value (false discovery rate if the P value is significant) cutoff of 0.2 (Table 1). In addition to Fbxw8, most of the down-regulated genes were muscle related. The only gene up-regulated in Fbxw8−/− embryos relative to heterozygous embryos was the IGFBP1 gene. Quantitative PCR analysis confirmed the elevated expression of IGFBP1 mRNA in Fbxw8−/− embryos compared to that in their heterozygous littermates (data not shown).
Increased IGFBP2 expression in Cul7−/− and Fbxw8−/− MEFs. We had previously noted that fibroblasts from Cul7−/− embryos grew more slowly than MEFs from their heterozygous or wild-type littermates (2). To determine if Fbxw8−/− MEFs also grew slowly, we prepared samples of Fbxw8+/+, Fbxw8+/−, and Fbxw8−/− MEFs from littermate embryos and determined their growth rates. Equal numbers of passage 2 MEFs were seeded into replicate plates, and the MEFs were fed every 2 days and counted. Fbxw8−/− MEFs grew more slowly than Fbxw8+/+ and Fbxw8+/− MEFs (Fig. (Fig.5A).5A
Given the growth defect observed in both Cul7−/− and Fbxw8−/− MEFs, we asked if any secreted proteins were differentially expressed in the tissue culture supernatant. Cul7−/− and wild-type MEFs were incubated in reduced-serum medium for 24 h, and supernatants were harvested for analysis by SDS-PAGE. Coomassie blue staining revealed a specific band at 32 kDa that showed consistent up-regulation in Cul7−/− MEFs compared to the level in wild-type MEFs (Fig. (Fig.5C).5C To determine if Fbxw8−/− MEFs also expressed higher levels of IGFBP2, lysates from wild-type, Cul7−/−, and Fbxw8−/− MEFs were blotted with an IGFBP2 antibody. Increased expression of intracellular IGFBP2 was detected in Fbxw8−/− as well as Cul7−/− MEFs compared to that in wild-type MEFs from littermate controls (FIG. (FIG.5E).5E Given the elevated levels of IGFBP2 in Cul7 and Fbxw8 mutant MEFs, we tested whether IGFBP2 could be targeted for ubiquitination and subsequent proteasomal destruction by the SKP1-CUL7-FBXW8 CRL complex. We did not observe any specific binding of IGFBP2 to CUL7 or FBXW8 (data not shown). In addition, the levels of IGFBP2 did not change in either mutant or wild-type MEFs when cells were treated with proteasome inhibitors (data not shown). Furthermore, when Fbxw8−/− and wild-type MEFS were treated with cycloheximide, we observed that the half-lives of IGFBP2 in wild-type and Fbxw8 null cells were similar (data not shown). Despite the repeated observation that IGFBP2 levels were elevated in Fbxw8−/− and Cul7−/− MEFs, we were unable to detect any evidence either that IGFBP2 was a direct substrate for ubiquitination and degradation or that its stability was affected by the CUL7-FBXW8 complex. The IGFBPs serve to modulate the availability of IGFs to activate the IGF1R tyrosine kinase and downstream signal transducers. To determine if the increased levels of IGFBP2 affected IGF1R signaling, MEFs were serum starved before stimulation with IGF1. In the absence of IGF1, the tyrosine phosphorylation of IGF1R was undetectable in wild-type as well as Cul7−/− and Fbxw8−/− MEFs. After stimulation with IGF1 for 15 min, tyrosine-phosphorylated IGF1R was readily detected in wild-type MEFs but was detected at reduced levels in Cul7−/− and Fbxw8−/− MEFs (Fig. (Fig.5F).5F DISCUSSION In this study, we demonstrated that Fbxw8−/− mice show a phenotype remarkably similar to that of Cul7−/− mice. Key similarities include normal embryonic development except for the significantly decreased sizes of mutant embryos and placentas relative to those of their wild-type and heterozygous littermates and neonatal death due to respiratory failure. A significant difference between the CUL7 and FBXW8 mutant phenotypes was that while all Cul7−/− mutant embryos died at birth, approximately 30% of Fbxw8−/− mice survived until weaning (2). Mutant Fbxw8 mice remained runted and grew more slowly than their littermates, although they were otherwise normal in appearance and behavior and did not develop any additional abnormalities. In addition to these developmental similarities, primary Fbxw8−/− and Cul7−/− MEFs grew more slowly than wild-type and heterozygous cells, indicating that the normal function of CUL7 and FBXW8 contributes to cellular proliferation. Different methods of gene disruption may account for the survival of some of the Fbxw8−/− mice and none of the Cul7−/− mice. Cul7−/− mice were generated using targeted recombination resulting in the excision of exons 2 to 4 of Cul7 (2). In contrast, Fbxw8−/− mice were generated by the gene trap method. The gene trap eliminated nearly all Fbxw8 expression, but a small amount of mRNA (<1% of the wild-type level) and protein was detected in the Fbxw8−/− MEFs and tissues (Fig. 1E and F Alternatively, the phenotype of the Cul7−/− mice may be more severe given the possibility that CUL7 may interact with additional F box-containing proteins to yield a more complex phenotype. By analogy, CUL1 is expected to bind many F box proteins, including β-transducin repeat-containing protein 1, SKP2, and FBXW7. The targeted disruption of Cul1 in mice results in embryonic lethality, whereas the disruption of the F box genes Btrc and Skp2 does not result in lethal phenotypes (20, 21, 34). The Fbxw7−/− phenotype is lethal to embryos but is much milder than the Cul1−/− phenotype (29, 31). These observations suggest that the severity of the Cul1 knockout may be due to its effects on multiple F box proteins and their corresponding substrates. Although CUL7 may bind specifically to additional F box proteins, we have failed to observe any specific interaction with an F box-containing protein other than FBXW8. It should be noted that CUL7 but not FBXW8 binds specifically to PARC and GLMN (25, 26). It is possible that the severity of the Cul7 null phenotype may reflect an adverse impact on these two proteins as well. It is not clear why the Cul7 null and Fbxw8 null embryos had difficulty inflating their lungs at birth. When we examined Fbxw8 null E18.5 embryos, all failed to inflate their lungs, indicating that this failure was the most significant defect that limited survival. This defect may reflect specific effects in the bronchial epithelial tissues, structural effects related to bone and cartilage development, or other features. It should be noted that a recent report on 3-M syndrome patients revealed a high frequency of respiratory distress at birth frequently necessitating mechanical ventilation (18). It was suggested that abnormal cartilaginous development may have led to respiratory distress in at least one of these 3-M syndrome patients. We took advantage of the gene trap construct that expressed β-Gal under the control of the endogenous Fbxw8 promoter to determine the relative levels of FBXW8 expression in embryonic tissue. FBXW8 was most highly expressed in skeletal muscle and placental labyrinthine tissues. In addition, FBXW8 was expressed in the growth plates of embryonic bones (Fig. (Fig.3).3 The IGF signaling pathway is an important contributor to fetal and postnatal growth and development. IGF2 is essential for normal mouse embryonic growth (6, 7), whereas IGF1 has a continuous function throughout development (4, 17). A series of mice carrying null mutations of IGF-related genes has been established. The knockout of IGF1, IGF2, IGF1R, or insulin receptor substrate 1 leads to prenatal and postnatal growth retardation, although mice with these mutations have some differences in body size (3, 6, 17, 23, 28). On the other hand, transgenic mice that overexpress IGFBP1 or IGFBP2 show growth retardation (11, 24). Among the null mutants, the Igf1r−/− phenotype is similar to the Cul7−/− phenotype, with small embryos that die at birth due to respiratory failure (17). In two independent analyses, we observed that the levels of IGFBP were increased in Fbxw8 mutant embryos and MEFs. Expression profiling revealed that the only gene significantly overexpressed in whole Fbxw8−/− mutant embryos was the IGFBP1 gene. In addition, the purification of secreted proteins from Cul7−/− MEFs revealed high levels of IGFBP2, and these increased levels were also observed in Fbxw8−/− MEFs. Furthermore, we observed a blunted response to IGF1R signaling in both Cul7−/− and Fbxw8−/− MEFs. The growth defect in Fbxw8 mutant embryos and mice may reflect disturbances in IGF signaling due to elevated levels of IGFBPs in the growth plate (33). These results raise the possibility that the loss of Fbxw8 perturbs the ability of bone and muscle to contribute to the overall growth of the mouse. Despite the consistent appearance of elevated levels of IGFBP2 in Fbxw8−/− MEFs, we were unable to demonstrate that IGFBP2 overexpression contributed to the slow growth of mutant MEFs. Notably, neither blocking antibodies to IGFBP2 that interfered with binding to IGF1 or siRNA that reduced levels of IGFBP increased the growth rate or affected the cell cycle profile of Fbxw8−/− MEFs. It is possible that increased IGFBP2 levels and decreased IGF1R activation may not contribute directly to the slow-growth phenotype in Cul7−/− or Fbxw8−/− MEFs and embryos. Although no studies of human 3-M syndrome patients have reported IGFBP levels, IGFBP isoforms may be elevated and serve as a biomarker of the disease. While CUL7 and FBXW8 have been detected in nearly all cell lines and tissues tested, differences in the levels of expression have been noted. For example, high levels of CUL7 and FBXW8 were detected in MEFs and HeLa cells while lower levels were observed in lymphoblastoid B-cell lines. Of note, we were unable to detect significant levels of FBXW8 protein expression in adult mouse brains (Fig. (Fig.2C).2C In addition to the reduced size of the Fbxw8 null mice, we observed a reduced growth rate of Fbxw8−/− MEFs compared to that of heterozygote and wild-type MEFs (Fig. (Fig.5A).5A During the preparation of this work, Tsunematsu and colleagues reported the phenotype of Fbxw8−/− mice generated by a conventional targeted knockout strategy (32). Similar to the results in our study, about one-third of Fbxw8 null mice in that study were born alive, despite severe defects in placental development. However, there were several differences from our study, including the deaths of approximately two-thirds of the Fbxw8−/− embryos between E12.5 and E17.5. In addition, it was reported that the lungs of the Fbxw8 knockout mutant embryos inflated well. Although we cannot rule out the possibility that some null embryos generated in our study died prior to birth, we have repeatedly observed the respiratory defect in the E18.5 Fbxw8 null embryos. Two recent studies revealed that CUL7 mutations were present in patients with 3-M syndrome, a disorder characterized by intrauterine growth retardation and severe postnatal dwarfism (12, 18). These mutations in CUL7 reduced the E3 ubiquitin ligase activity of CUL7 and disrupted the interaction of CUL7 with FBXW8 and SKP1. Interestingly, Yakut patients with the 3-M short-stature syndrome have few bone abnormalities but have a high frequency of neonatal respiratory distress and abnormal vascularization of the fetal placenta (18). These phenotypes were very similar to those observed in Fbxw8−/− as well as Cul7−/− mice. It is noteworthy that the small size and decreased growth rate of the mutant Fbxw8 mice may predict that individuals with other short-stature syndromes, or with non-CUL7 related 3-M syndrome, may have mutations in the FBXW8 gene. [Supplemental material]
Acknowledgments This work was supported in part by Public Health Service grant RO1 CA093804 from the National Cancer Institute. T.T. was supported in part by the Toyobo Biotechnology Foundation. We thank Roderick Bronson and Gerald Chu at the Dana-Farber/Harvard Cancer Center Rodent Histopathology Core, William Lane at the Harvard Microchemistry and Proteomics Analysis Facility, and Edward Fox at the Dana-Farber Microarray Core Facility. The ES cell line was obtained from the National Heart, Lung, and Blood Institute-funded Program for Genomic Applications at BayGenomics. We thank Elizabeth Bland and Peter Scambler for identifying the CUL7 mutation in the 3-M syndrome patient cell line. Footnotes Published ahead of print on 12 November 2007.†Supplemental material for this article may be found at http://mcb.asm.org/. REFERENCES 1. Ali, S. H., J. S. Kasper, T. Arai, and J. A. DeCaprio. 2004. Cul7/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J. Virol. 782749-2757. [PubMed] 2. Arai, T., J. S. Kasper, J. R. Skaar, S. H. Ali, C. Takahashi, and J. A. DeCaprio. 2003. Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis. Proc. Natl. Acad. Sci. USA 1009855-9860. [PubMed] 3. Araki, E., M. A. Lipes, M. E. Patti, J. C. Bruning, B. Haag, III, R. S. Johnson, and C. R. Kahn. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372186-190. [PubMed] 4. Baker, J., J. P. Liu, E. J. Robertson, and A. Efstratiadis. 1993. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 7573-82. [PubMed] 5. Choe, S. E., M. Boutros, A. M. Michelson, G. M. Church, and M. S. Halfon. 2005. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 6R16. [PubMed] 6. DeChiara, T. M., A. Efstratiadis, and E. J. Robertson. 1990. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 34578-80. [PubMed] 7. DeChiara, T. M., E. J. Robertson, and A. Efstratiadis. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64849-859. [PubMed] 8. Deshaies, R. J. 1999. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 15435-467. [PubMed] 9. Dias, D. C., G. Dolios, R. Wang, and Z. Q. Pan. 2002. CUL7: a DOC domain-containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex. Proc. Natl. Acad. Sci. USA 9916601-16606. [PubMed] 10. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67425-479. [PubMed] 11. Hoeflich, A., M. Wu, S. Mohan, J. Foll, R. Wanke, T. Froehlich, G. J. Arnold, H. Lahm, H. J. Kolb, and E. Wolf. 1999. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1405488-5496. [PubMed] 12. Huber, C., D. Dias-Santagata, A. Glaser, J. O'Sullivan, R. Brauner, K. Wu, X. Xu, K. Pearce, R. Wang, M. L. Uzielli, N. Dagoneau, W. Chemaitilly, A. Superti-Furga, H. Dos Santos, A. Megarbane, G. Morin, G. Gillessen-Kaesbach, R. Hennekam, I. Van der Burgt, G. C. Black, P. E. Clayton, A. Read, M. Le Merrer, P. J. Scambler, A. Munnich, Z. Q. Pan, R. Winter, and V. Cormier-Daire. 2005. Identification of mutations in CUL7 in 3-M syndrome. Nat. Genet. 371119-1124. [PubMed] 13. Jackson, P. K., and A. G. Eldridge. 2002. The SCF ubiquitin ligase: an extended look. Mol. Cell 9923-925. [PubMed] 14. Jin, J., T. Cardozo, R. C. Lovering, S. J. Elledge, M. Pagano, and J. W. Harper. 2004. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 182573-2580. [PubMed] 15. Kasper, J. S., H. Kuwabara, T. Arai, S. H. Ali, and J. A. DeCaprio. 2005. Simian virus 40 large T antigen's association with the CUL7 SCF complex contributes to cellular transformation. J. Virol. 7911685-11692. [PubMed] 16. Li, J., X. Zhu, M. Chen, L. Cheng, D. Zhou, M. M. Lu, K. Du, J. A. Epstein, and M. S. Parmacek. 2005. Myocardin-related transcription factor B is required in cardiac neural crest for smooth muscle differentiation and cardiovascular development. Proc. Natl. Acad. Sci. USA 1028916-8921. [PubMed] 17. Liu, J. P., J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 7559-72. [PubMed] 18. Maksimova, N., K. Hara, A. Miyashita, I. Nikolaeva, A. Shiga, A. Nogovicina, A. Sukhomyasova, V. Argunov, A. Shvedova, T. Ikeuchi, M. Nishizawa, R. Kuwano, and O. Onodera. 3 August 2007, posting date. Clinical, molecular and histopathological features of short stature syndrome with novel CUL7 mutation in Yakuts: new population isolate in Asia. J. Med. Genet. doi: doi: 10.1136/jmg.2007.051979.. [PubMed] 19. Nakamura, E., E. L. P. Abreu, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G. J. Zhang, K. Kondo, V. Nose, and W. G. Kaelin, Jr. 2006. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am. J. Pathol 168574-584. [PubMed] 20. Nakayama, K., S. Hatakeyama, S. Maruyama, A. Kikuchi, K. Onoe, R. A. Good, and K. I. Nakayama. 2003. Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc. Natl. Acad. Sci. USA 1008752-8757. [PubMed] 21. Nakayama, K., H. Nagahama, Y. A. Minamishima, M. Matsumoto, I. Nakamichi, K. Kitagawa, M. Shirane, R. Tsunematsu, T. Tsukiyama, N. Ishida, M. Kitagawa, K. Nakayama, and S. Hatakeyama. 2000. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 192069-2081. [PubMed] 22. Nakayama, K. I., and K. Nakayama. 2005. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 16323-333. [PubMed] 23. Powell-Braxton, L., P. Hollingshead, C. Warburton, M. Dowd, S. Pitts-Meek, D. Dalton, N. Gillett, and T. A. Stewart. 1993. IGF-I is required for normal embryonic growth in mice. Genes Dev. 72609-2617. [PubMed] 24. Rajkumar, K., D. Barron, M. S. Lewitt, and L. J. Murphy. 1995. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1364029-4034. [PubMed] 25. Skaar, J. R., T. Arai, and J. A. DeCaprio. 2005. Dimerization of CUL7 and PARC is not required for all CUL7 functions and mouse development. Mol. Cell. Biol. 255579-5589. [PubMed] 26. Skaar, J. R., L. Florens, T. Tsutsumi, T. Arai, A. Tron, S. K. Swanson, M. P. Washburn, and J. A. DeCaprio. 2007. PARC and CUL7 form atypical cullin RING ligase complexes. Cancer Res. 672006-2014. [PubMed] 27. Stryke, D., M. Kawamoto, C. C. Huang, S. J. Johns, L. A. King, C. A. Harper, E. C. Meng, R. E. Lee, A. Yee, L. L'Italien, P. T. Chuang, S. G. Young, W. C. Skarnes, P. C. Babbitt, and T. E. Ferrin. 2003. BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res. 31278-281. [PubMed] 28. Tamemoto, H., T. Kadowaki, K. Tobe, T. Yagi, H. Sakura, T. Hayakawa, Y. Terauchi, K. Ueki, Y. Kaburagi, S. Satoh, et al. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372182-186. [PubMed] 29. Tetzlaff, M. T., W. Yu, M. Li, P. Zhang, M. Finegold, K. Mahon, J. W. Harper, R. J. Schwartz, and S. J. Elledge. 2004. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl. Acad. Sci. USA 1013338-3345. [PubMed] 30. Todaro, G. J., and H. Green. 1963. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17299-313. [PubMed] 31. Tsunematsu, R., K. Nakayama, Y. Oike, M. Nishiyama, N. Ishida, S. Hatakeyama, Y. Bessho, R. Kageyama, T. Suda, and K. I. Nakayama. 2004. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J. Biol. Chem. 2799417-9423. [PubMed] 32. Tsunematsu, R., M. Nishiyama, S. Kotoshiba, T. Saiga, T. Kamura, and K. I. Nakayama. 2006. Fbxw8 is essential for Cul1-Cul7 complex formation and for placental development. Mol. Cell. Biol. 266157-6169. [PubMed] 33. van der Eerden, B. C., M. Karperien, and J. M. Wit. 2003. Systemic and local regulation of the growth plate. Endocr. Rev. 24782-801. [PubMed] 34. Wang, Y., S. Penfold, X. Tang, N. Hattori, P. Riley, J. W. Harper, J. C. Cross, and M. Tyers. 1999. Deletion of the Cul1 gene in mice causes arrest in early embryogenesis and accumulation of cyclin E. Curr. Biol. 91191-1194. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Annu Rev Biochem. 1998; 67():425-79.
[Annu Rev Biochem. 1998]Annu Rev Cell Dev Biol. 1999; 15():435-67.
[Annu Rev Cell Dev Biol. 1999]Mol Cell. 2002 May; 9(5):923-5.
[Mol Cell. 2002]Genes Dev. 2004 Nov 1; 18(21):2573-80.
[Genes Dev. 2004]J Virol. 2004 Mar; 78(6):2749-57.
[J Virol. 2004]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16601-6.
[Proc Natl Acad Sci U S A. 2002]J Virol. 2005 Sep; 79(18):11685-92.
[J Virol. 2005]Semin Cell Dev Biol. 2005 Jun; 16(3):323-33.
[Semin Cell Dev Biol. 2005]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Nat Genet. 2005 Oct; 37(10):1119-24.
[Nat Genet. 2005]J Med Genet. 2007 Dec; 44(12):772-8.
[J Med Genet. 2007]Nucleic Acids Res. 2003 Jan 1; 31(1):278-81.
[Nucleic Acids Res. 2003]J Cell Biol. 1963 May; 17():299-313.
[J Cell Biol. 1963]Am J Pathol. 2006 Feb; 168(2):574-84.
[Am J Pathol. 2006]Genome Biol. 2005; 6(2):R16.
[Genome Biol. 2005]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Mol Cell Biol. 2006 Aug; 26(16):6157-69.
[Mol Cell Biol. 2006]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16601-6.
[Proc Natl Acad Sci U S A. 2002]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Nat Genet. 2005 Oct; 37(10):1119-24.
[Nat Genet. 2005]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]J Cell Biol. 1963 May; 17():299-313.
[J Cell Biol. 1963]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2005 Jun 21; 102(25):8916-21.
[Proc Natl Acad Sci U S A. 2005]Proc Natl Acad Sci U S A. 2003 Jul 22; 100(15):8752-7.
[Proc Natl Acad Sci U S A. 2003]EMBO J. 2000 May 2; 19(9):2069-81.
[EMBO J. 2000]Curr Biol. 1999 Oct 21; 9(20):1191-4.
[Curr Biol. 1999]Proc Natl Acad Sci U S A. 2004 Mar 9; 101(10):3338-45.
[Proc Natl Acad Sci U S A. 2004]J Biol Chem. 2004 Mar 5; 279(10):9417-23.
[J Biol Chem. 2004]J Med Genet. 2007 Dec; 44(12):772-8.
[J Med Genet. 2007]Nature. 1990 May 3; 345(6270):78-80.
[Nature. 1990]Cell. 1991 Feb 22; 64(4):849-59.
[Cell. 1991]Cell. 1993 Oct 8; 75(1):73-82.
[Cell. 1993]Cell. 1993 Oct 8; 75(1):59-72.
[Cell. 1993]Nature. 1994 Nov 10; 372(6502):186-90.
[Nature. 1994]Endocr Rev. 2003 Dec; 24(6):782-801.
[Endocr Rev. 2003]Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9855-60.
[Proc Natl Acad Sci U S A. 2003]Mol Cell Biol. 2006 Aug; 26(16):6157-69.
[Mol Cell Biol. 2006]Nat Genet. 2005 Oct; 37(10):1119-24.
[Nat Genet. 2005]J Med Genet. 2007 Dec; 44(12):772-8.
[J Med Genet. 2007]